NCT06156527View on ClinicalTrials.gov

A Randomized Phase II Study of LAZE rtiNib Alone Versus Lazertinib Plus bevaCizumab for NSCLC With EGFR + & Smoker

PHASE2RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

September 5, 2023

Primary Completion Date

September 5, 2026

Study Completion Date

December 31, 2026

Conditions
Lazertinib
Interventions
DRUG

Lazertinib

Lazertinib 240mg, QD, daily

DRUG

Bevacizumab Injectable Product

Bevacizumab: 15mg/kg IV every 3 weeks

Trial Locations (5)

10408

RECRUITING

National Cancer Center, Goyang-si

16247

NOT_YET_RECRUITING

The Catholic University of Korea, St. Vincent's Hospital, Suwon

16499

NOT_YET_RECRUITING

AJOU university hospital, Suwon

03722

NOT_YET_RECRUITING

Yonsei University Health System, Severance Hospital, Seoul

06273

NOT_YET_RECRUITING

Gangnam Severance Hospita, Seoul

All Listed Sponsors
lead

National Cancer Center, Korea

OTHER_GOV